7.1.3.7	  Risk-adapted treatment for clinical stage I non-seminomatous germ cell tumour based on vascular   invasion,
Summary of evidence,LE
Lymphovascular invasion increases the risk of relapse.,2a
"The relapse rate with active surveillance is up to 50%, depending on LVI status.",2a
The relapse rate in patients who receive adjuvant chemotherapy with BEP (x 1 cycle) is up to 3%.,2a
Adjuvant chemotherapy with BEP is superior to adjuvant RPLND in terms of the risk of relapse.,1b
"A risk-adapted approach, based on lymphovascular invasion is feasible.",2b
The acute toxicity of one cycle adjuvant BEP is low.,1b
